The latest update is out from Virpax Pharmaceuticals (VRPX).
Virpax Pharmaceuticals has secured a $2.5 million investment through a Securities Purchase Agreement with an institutional investor. This deal, which includes a high-interest senior secured promissory note due by the end of 2025, aims to settle litigation liabilities and reshape the company’s board. The investor now influences board composition, with the appointment of four new members and the resignation of five existing ones. Additionally, this transaction paves the way for further potential financing opportunities, subject to specific terms and investor rights until September 30, 2024.
For detailed information about VRPX stock, go to TipRanks’ Stock Analysis page.
